A Single-center, Open-label, Two-period, Two-treatment, Crossover, Single-dose Study in Healthy Female and Male Subjects to Assess the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of ACT-129968
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Setipiprant (Primary)
- Indications Allergic rhinitis; Asthma; Seasonal allergic rhinitis
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 19 Jun 2013 New trial record